We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

MEDIX BIOCHEMICA AB

Develops, produces and markets monoclonal antibodies, antibody services and recombinant antigens for IVD industry, as... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Medix Biochemica Acquires IVD Raw Materials Producer Bioresource Technology

By LabMedica International staff writers
Posted on 21 Jun 2022
Print article
Image: Medix Biochemica has broadened its capabilities in diagnostic base matrices through the acquisition of BRT (Photo courtesy of Pexels)
Image: Medix Biochemica has broadened its capabilities in diagnostic base matrices through the acquisition of BRT (Photo courtesy of Pexels)

Medix Biochemica (Espoo, Finland) has acquired 100% of the shares of Bioresource Technology (BRT, Weston, FL, USA) to broaden its base matrix capabilities and further strengthen its local presence in the US market. As a result of this partnership, Medix will provide its customers with a comprehensive offering of raw materials for their in vitro diagnostics (IVD) quality control products.

BRT is a leading provider of high-quality base matrices and other critical raw materials to many of the largest IVD manufacturers across the world, with a focus on manufacturing immunoassay, clinical chemistry and molecular diagnostic assay and QC materials. BRT’s organization and operations will form a significant part of Medix’s IVD Biomaterials Business Unit, which also comprises manufacturing of native antigens, enzymes, proteins and biological.

“Together, we have the potential to broaden our offering to IVD companies across the globe,” said Steve Ferguson, CEO of Medix Biochemica. “There is an excellent complementary offering between our portfolios, enabling Medix Biochemica to be a comprehensive partner for IVD companies requiring quality raw materials for QC products. With our complete offering of biological samples, processed plasma, base matrices, native enzymes, proteins, antibodies or antigens and our depth of expertise, we can dramatically reduce time to market for IVD companies whatever their need. Our vision is to be the first-choice partner for the IVD industry, and the team at BRT takes us one step closer.”

“We are excited about joining Medix Biochemica,” addd Derik Reichenbach, President of BRT. “Building long-term relationships with our customers have always been key to our success and together with Medix Biochemica’s global team, we are now able to reach even more IVD customers across the globe. We are very much looking forward to contributing to the strong growth of Medix Biochemica.”

Related Links:
Medix Biochemica 
Bioresource Technology 

New
Gold Supplier
Auto Urinary Sediment Analyzer
EH-2030
New
Gold Supplier
Infectious Diseases Controls
Multichem ID-SeroNeg
New
Legionella Pneumophila Assay
C4Legio LFA
New
Automated Nucleic Acid Extraction System
GenoXtract fleXT

Print article

Channels

Molecular Diagnostics

view channel
Image: A new blood test could noninvasively and inexpensively detect colorectal cancer (Photo courtesy of Pexels)

Novel Blood Test Could Detect Early-Onset Colorectal Cancer

Colorectal cancer is the fourth most common cancer, according to the U.S. Centers for Disease Control and Prevention. The rate of colon or rectal cancers in people younger than 50 years old has been on... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.